Epidemiological Insights into Invasive Fungal Rhinosinusitis among COVID-19 Inpatients: Unveiling Diverse Pathogens with implications on cancer patients
DOI:
https://doi.org/10.56294/hl2025591Keywords:
Acute Invasive Fungal Rhino-Sinusitis (AIFRS), COVID-19 Inpatients, Epidemiology, Pathogen Diversity, Coexisting InfectionsAbstract
The emergence of invasive fungal rhinosinusitis (IFRS), as well as COVID-19 at the same time, poses a challenge to patients receiving treatment in hospitals. Research have shown various infections caused by fungi that relate to the epidemiology of invasive fungal rhinosinusitis among patients suffering from COVID-19. In this retrospective analysis, examined mycological investigations, subject characteristics, clinical manifestations, antifungal drugs used and length of illness among 68 patients diagnosed with Acute Invasive Fungal Rhino-Sinusitis (AIFRS). The research results indicated that steroid therapy was applied in 32.81% of cases and more than half of examines were men. The necessity for early detection is highlighted by the variety of clinical symptoms of headaches (22.40%). Tissue culture, histological analysis and molecular identification of culture isolates were all part of the mycological research. Amphotericin B (30.21%) and Nystatin (22.40%) were the antifungal drugs utilized, indicating a customized approach to therapy. The length of the disease varied by 22.92% of patients reported symptoms lasting between 16 and 30 days. The age distribution showed that the 50 to 59 age group accounted for a significant amount (13.02%). The research highlights the vital need for caution while identifying and treating AIFRS in COVID-19 inpatients, with a focus on a variety of infections and specialized treatment modalities.
References
1. Basile K, Halliday C, Kok J, Chen SC. Fungal infections other than invasive aspergillosis in COVID-19 patients. Journal of fungi. 2022 Jan 6;8(1):58.https://doi.org/10.3390/jof8010058
2. Ramanathan V, PariThenmozhi H, Singh R, Bheemanathi Hanuman S, Adithan S. Corticosteroids and invasive fungal infections in hospitalized COVID-19 patients–A single-center cross-sectional study. F1000Research. 2023 Oct 6;12:1282..https://doi.org/10.7759/cureus.21054
3. Ezeokoli OT, Gcilitshana O, Pohl CH. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. Journal of Fungi. 2021 Jul 9;7(7):545.https://doi.org/10.3390/jof7070545
4. Kulkarni R, Pujari S, Gupta D, Advani S, Soni A, Duberkar D, et al. Rhino-orbito-cerebral mycosis and COVID-19: From bad to worse?. Annals of Indian Academy of Neurology. 2022 Jan; 25(1):68.https://doi.org/10.4103%2Faian.aian_463_21
5. Reddy YM, Shankar T, Sreenivas K, Kumar M. Significance of laboratory diagnosis in coronavirus disease associated invasive fungal sinusitis from an otolaryngologist perspective: A Retrospective Study at a tertiary care nodal centre. Open J Clin Med Images. 2022;2(1):1031.
6. Tadros D, Tomoum MO, Shafik HM. Orbital Complications of Acute Invasive Fungal Rhinosinusitis: A New Challenge in the COVID-19 Convalescent Patients. Clinical Ophthalmology (Auckland, NZ). 2022;16:4011.https://doi.org/10.2147%2FOPTH.S391188
7. Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19-associated mucormycosis presenting to the Emergency Department—an observational study of 70 patients. QJM: An International Journal of Medicine. 2021 Jul 1;114(7):464-70.https://doi.org/10.1093/qjmed/hcab190
8. Sathe NU, Jegarkal A, Thangi LP, Magdum r. Septal perforation & nose the most common presenting site in post covid 19 invasive fungal rhinosinusitis: our experience.https://doi.org/10.37118/ijdr.23651.01.2022
9. Lusida M, Arifijanto MV, Rachman BE, Alkaff FF. Difficulty in management of acute invasive fungal rhinosinusitis in Indonesia during the COVID-19 pandemic: A case report. Respiratory Medicine Case Reports. 2023 Jan 1;46:101916.https://doi.org/10.1016%2Fj.rmcr.2023.101916
10. Behairy EA, Shafy IA, Torky MA, Eldemerdash AA. Schematic approach of post Covid-19 acute invasive fungal sinusitis. Menoufia Medical Journal. 2023;36(3):16.http://dx.doi.org/10.59204/2314-6788.1108
11. FarghlyYoussif S, Abdelrady MM, Thabet AA, Abdelhamed MA, Gad MO, Abu-Elfatth AM, et al. COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma. Scientific Reports. 2022 Jun 21;12(1):10494.https://doi.org/10.1038/s41598-022-13443-3
12. Tabarsi P, Khalili N, Pourabdollah M, Sharifynia S, Naeini AS, Ghorbani J, et al. Case report: COVID-19-associated rhinosinusitismucormycosis caused by Rhizopusarrhizus: a rare but potentially fatal infection occurring after treatment with corticosteroids. The American journal of tropical medicine and hygiene. 2021 Aug;105(2):449.https://doi.org/10.4269%2Fajtmh.21-0359
13. 13-Boorgula SY, Yelamanchili S, Sistla SK, Saher L, Gujjarlapudi D, E S, V SD, Duvvur NR. An Experience in Laboratory Diagnosis of Fungal Infections in COVID-19 Patients. International Archives of Otorhinolaryngology. 2023 Sep 26.DOI https://doi.org/ 10.1055/s-0043-1768140
14. 14-Elzar A, Eldeeb A, Aldegla HE. Invasive Fungal Sinusitis Associated with COVID-19. Mansoura Medical Journal. 2022 Sep 1;51(3):139-53.https://dx.doi.org/10.21608/mjmu.2022.129792.1092
15. Ismaiel WF, Abdelazim MH, Eldsoky I, Ibrahim AA, Alsobky ME, Zafan E, et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. American journal of otolaryngology. 2021 Nov 1;42(6):103080.https://doi.org/10.1016/j.amjoto.2021.103080
16. El-Kholy NA, El‐Fattah AM, Khafagy YW. Invasive fungal sinusitis in post COVID‐19 patients: a new clinical entity. The Laryngoscope. 2021 Dec;131(12):2652-8.https://doi.org/10.1002/lary.29632
17. Sebastian SK, Ponnuvelu S, Sharma Y, Jha RK. A comparative study on the clinical profile of COVID-related and non-COVID-related acute invasive fungal rhino sinusitis. European Archives of Oto-Rhino-Laryngology. 2022 Nov;279(11):5239-46.https://doi.org/10.1007/s00405-022-07402-x
18. Baghel SS, Keshri AK, Mishra P, Marak R, Manogaran RS, Verma PK, et al. The spectrum of invasive fungal sinusitis in COVID-19 patients: experience from a tertiary care referral center in Northern India. Journal of Fungi. 2022 Feb 24;8(3):223.https://doi.org/10.3390/jof8030223
19. Singh V, Prasad A, Panda PK, Totaganti M, Tyagi AK, Thaduri A, et al. Mixed invasive fungal infections among COVID-19 patients. Current Medical Mycology. 2021 Dec;7(4):19.https://doi.org/10.18502%2Fcmm.7.4.8407
20. Donovan MR, Miglani A, Lal D, Marino MJ. Factors associated with invasive fungal sinusitis in patients with COVID‐19: A systematic review and single‐center case series. Laryngoscope investigative otolaryngology. 2022 Aug;7(4):913-9.https://doi.org/10.1002/lio2.833
21. Khan S, Anwar K, Mohammad AY, Saleem W, Ilyas M, Nauman a. Fungal rhinosinusitis in the co-morbid covid-19 positive patients-a retrospective analysis. Pakistan postgraduate medical journal. 2019 dec 28;30(04):1527.https://doi.org/10.51642/ppmj.v30i04.567
22. Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Japanese journal of ophthalmology. 2021 Jul;65(4):515-25.https://doi.org/10.1007/s10384-021-00845-5
23. Kaur P, Arora M, Sood AS, Singh A. Microbiological and Radiological Perspective of Fungal Rhinosinusitis during the Covid-19 Pandemic: A Prospective Observational Study in A Tertiary Care Centre in Northern India. Journal of Pure & Applied Microbiology. 2021 Dec 1;15(4).https://doi.org/10.22207/JPAM.15.4.70
24. Pradhan P, Shaikh Z, Mishra A, Preetam C, Parida PK, Sarkar S, et al. Predisposing factors of rhino-orbital-cerebral mucormycosis in patients with COVID 19 infection. Indian Journal of Otolaryngology and Head & Neck Surgery. 2021 Sep 25:1-7.https://doi.org/10.1007/s12070-021-028754
25. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, SoniS,et al. A national strategy to diagnose coronavirus disease 2019–associated invasive fungal disease in the intensive care unit. Clinical Infectious Diseases. 2021 Oct 1;73(7):e1634-44.https://doi.org/10.1093/cid/ciaa1298.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pradeepta Sekhar Patro, Avinash Mane , Esha Rami, Varun Ojha, Vaibhav Kaushik, Vundela Swathi (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
